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ABSTRACT 
Breast cancer is a heterogeneous group of neoplasms predominantly originating in the 
terminal duct lobular units. It represents the leading cause of cancer death in women 
and the survival frequencies for patients at advanced stages of the disease remain low. 
New treatment options need to be researched to improve these rates. The anti-tumor 
ether lipid edelfosine (ET) is the prototype of a novel generation of promising anticancer 
drugs. However it presents several drawbacks for its use in cancer therapy, including 
gastrointestinal and hemolytic toxicity and low oral bioavailability. To overcome these 
obstacles, ET was encapsulated in Precirol ATO 5 lipid nanoparticles (ET-LN), and its 
anti-tumor potential was in vitro tested in breast cancer. The formulated ET-LN were 
more effective in inhibiting cell proliferation and notably decreased cell viability, showing 
that the cytotoxic effect of ET was considerably enhanced when ET was encapsulated. 
In addition, ET and ET-LN were able to promote cell cycle arrest at G1 phase. 
Moreover, although both treatments provoked an apoptotic effect in a time-dependent 
manner, such anti-tumor effects were noticeably improved with ET-LN treatment. 
Therefore, our results indicate that encapsulating ET in LN played an essential role in 
improving the efficacy of the drug. 
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 1. Introduction 
Breast cancer is a heterogeneous group of neoplasms, predominantly originating in the 
terminal duct lobular units, regardless of histological type (Weigelt and Reis-Filho, 2009; 
Wellings and Jensen, 1973; Wellings et al., 1975). It represents the fifth most common 
cancer worldwide, the second most common cause of cancer death and the leading 
cause of cancer death in women (Siegel et al., 2013). The global burden of breast 
cancer exceeds all other cancers and the incidence rates of breast cancer are 
increasing. The ability of breast cancer cells to metastasize to distant organs makes this 
disease refractory and incurable and is the key factor in the treatment and prognosis of 
breast cancer (Lu and Kang, 2007). Current treatment approaches usually involve 
intrusive processes, chemotherapy to shrink any cancer present, surgery to then 
remove the tumor if possible, followed by more chemotherapy and radiation. However, 
the survival rates for patients at advanced stages of the disease remain low (Siegel et 
al., 2013). Consequently, new treatment options have to be studied to improve these 
rates. Current research areas include, on the one hand, the development of carriers that 
allow alternative dosing routes and reduce toxicity; and on the other, new therapeutic 
targets such as blood vessels fueling tumor growth and targeted therapeutics that are 
more specific in their activity (Brannon-Peppas and Blanchette, 2004).  
 
The anti-tumor ether lipid edelfosine (ET-18-OCH3, ET) has been shown as an effective 
anti-tumor agent in different malignancies (Estella-Hermoso de Mendoza et al., 2009a; 
Mollinedo et al., 2010a; Na and Surh, 2008; Shafer and Williams, 2003). However, 
when it is administered in its free form, it presents several drawbacks such as dose-
dependent hemolytic toxicity after intravenous administration (Ahmad et al., 1997), poor 
oral bioavailability and gastrointestinal irritation when administered orally (Estella-
Hermoso de Mendoza et al., 2009a; Estella-Hermoso de Mendoza et al., 2012; 
Houlihan et al., 1995; Munder and Westphal, 1990). 
 
Owing to the drawbacks of this molecule, new drug delivery systems have been 
designed (Estella-Hermoso de Mendoza et al., 2012). Lipid nanoparticles (LN) are 
colloidal transporters composed of a biocompatible and biodegradable lipid matrix. They 
are passively targeted at the tumor tissue due to the well-known enhanced permeability 
and retention effect (EPR), resulting in an increased concentration of drug in tumor cells 
and in lower side effects (Peer et al., 2007; Torchilin, 2011). Besides, LN can be 
administered orally and are mainly absorbed via the lymphatic system, circumventing 
first-pass hepatic metabolism, and thereby opening a new window in the treatment of 
cancer metastases (Estella-Hermoso de Mendoza et al., 2012; Lasa-Saracibar et al., 
2012). Moreover, LN may modify the entrance mechanism of the ET into cancer cells 
and this might overcome the resistance that some cell lines show to the free drug, 
(Wagner et al., 1998). In this context, the potential of ET-LN in overcoming the 
resistance of cancer cells has recently been proved in leukemic cell lines (Lasa-
Saracibar et al., 2013). 
 
The purpose of this study was to develop LN loaded with ET to enhance its therapeutic 
activity against breast cancer cells. We formulated ET-LN and we characterized their 
physicochemical properties. The cytotoxicity of ET-LN, their effects in cell cycle and the 
cell death induction mechanisms in breast cancer were also investigated. 
 
2. Material and Methods  
 
2.1. Chemicals 
ET was from Apointech (Salamanca, Spain). Precirol ATO 5 was a gift from Gattefossé 
(Lyon, France). Tween® 80 was obtained from Roig Farma (Barcelona, Spain). 
Phosphate-buffered saline (PBS; 10 mM phosphate, 0.9% NaCl), 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT), Trypan Blue, RNase and Propidium 
iodide (PI) were obtained from Sigma-Aldrich (Madrid, Spain). Chloroform was 
purchased from Panreac (Madrid, Spain) and methanol was obtained from Merck 
(Barcelona, Spain). Ultra-purified water was used throughout and all other chemicals 
were of analytical grade. 
 
2.2. Cell Culture 
MCF7 breast cancer cells were purchased from ATCC (American Type Culture 
Collection, Manassas, VA, USA). Dubelcco's modified Eagle's medium (DMEM), heat-
inactivated fetal bovine serum (FBS), trypsin–EDTA and penicillin–streptomycin 
mixtures were purchased from Gibco® BRL (Carlsbad, CA, USA).  
MCF7 breast cancer cell line was grown in DMEM supplemented with 50 U/mL 
penicillin, 50 U/mL streptomycin and 10% FBS at 37˚C in a humidified incubator 
supplemented with 5% carbon dioxide. 
 
2.3. Preparation of LN  
ET-LN formulations were prepared by the hot homogenization method followed by high 
shear homogenization and ultrasonication as previously described (Estella-Hermoso de 
Mendoza et al., 2012). The lipid phase consisted of 300 mg of Precirol ATO 5 with 30 
mg ET, while the aqueous phase consisted of 10 mL of a 2% (w/v) Tween® 80 aqueous 
solution. The nanoparticle suspension obtained was subsequently cooled in an ice bath 
and washed twice with filtered water by diafiltration with Amicon Ultra-15 filters of 
10,000 Da molecular weight cut-off membranes (Millipore®, Cork, Ireland) to remove 
the excess of surfactant and non-incorporated drug. LN were then resuspended in 3% 
trehalose (75% of the Precirol ATO 5 weigh) and the suspension was kept at -80ºC and 
freeze-dried to preserve the formulation for further studies. Blank (unloaded) 
nanoparticles (B-LN) were formulated as empty control of LN for in vitro experiments 
using an identical procedure.  
 
2.4. Nanoparticle characterization 
 
2.4.1. Particle size and Zeta potential 
Nanoparticle size and polydispersity index (PDI) of LN were determined in triplicate by 
photon correlation spectroscopy and zeta potential by laser doppler anemometry, using 
a Zetasizer Nano (Malvern, UK). Each sample was diluted 30-fold in distilled water until 
the appropriate concentration of particles was achieved to avoid multiscattering events. 
Similarly, the zeta potential was measured using the same equipment with a 
combination of laser doppler electrophoresis (Clogston and Patri, 2011; Kaszuba et al., 
2010). Each experiment was performed in triplicate. All data are expressed as a mean 
value ± standard deviation. 
 
2.4.2. Encapsulation efficiency and loading capacity 
Encapsulated ET was quantified by a previously validated ultra-high performance liquid 
chromatography-tandem mass spectrometry method as previously validated (Estella-
Hermoso de Mendoza et al., 2009b). The drug was extracted from a sample of 5 mg of 
lyophilized LN, to which 1 mL of chloroform was added in order to dissolve them and 
subsequently 3 ml of methanol were added to the mixture. After vortex mixing for 1 min 
at room temperature and centrifuging at 20,000 × g for 10 min, 2 μl aliquots of the 
supernatant were injected into the chromatographic system.  
 
2.5. Cytotoxicity studies 
The cytotoxic potential of ET-LN was evaluated with the MTT assay. 21000 cells/cm2 
were grown in 96-well plates in the presence of increasing amounts of ET or equivalent 
concentrations of ET-LN for 72 h. B-LN were also tested as control. Then, MTT solution 
was added directly to the culture media at a final concentration of 0.5 mg/mL and then 
incubated for 3 h at 37ºC. Afterwards, MTT containing medium was removed from all 
wells and the remaining cells containing formazan crystals were dissolved in DMSO. 
Optical density was determined with a BioRad microplate reader at 570 nm after 
background correction at 690 nm. Average cell viability of treated cells was expressed 
as a percentage of the absorbance of control cells. Untreated cells were taken as 
control with 100% viability and cells grown in presence of 10% DMSO were used as 
positive control of cytotoxicity. All experiments were performed in triplicate. 
 
Cell number and viability, as denoted by Trypan Blue exclusion, were calculated by cell 
counting with a Bright-Line Hemacytometer (Sigma-Aldrich, Madrid, Spain). Cell counts 
were performed in triplicate. 
 
Images of the morphological changes induced by ET and LN were obtained using a 
Nikon Eclipse TS100 microscope.  
 2.6. Cell cycle analysis 
For cell cycle evaluation, 21000 cells/cm2 were seeded in 6-well plates and incubated 
with 20 μg/mL of ET or equivalent concentrations of ET-LN. B-LN were also tested as 
control. Cells were trypsinized, collected by centrifugation, washed with PBS and fixed 
with 70% ethanol at 4ºC for 1 h. Next, cells were incubated with 0.45 units/mL RNase 
and stained with 10 μg/mL of propidium bromide. Cell fluorescence was detected on a 
FACSCalibur flow cytometer (BD Biosciences, Madrid, Spain) and analyzed with 
CellQuest Pro (BD Biosciences) and FlowJo data analysis software package (TreeStar, 
USA). All experiments were performed in triplicate after 48 and 72 h of incubation with 
the corresponding treatments. 
 
2.7.  Assessment of apoptosis by Annexin-V FITC staining 
For evaluation of apoptosis in MCF7 cells after ET and LN treatments, 21000 cells/cm2 
were seeded in 6-well plates and incubated with 20 μg/mL of ET or equivalent 
concentrations of ET-LN. B-LN were also tested as control. After 24, 48 or 72 h of 
incubation, cells were collected and washed twice with PBS and subsequently labeled. 
Two different approaches were used for the assessment of apoptosis induction of MCF7 
cells. 
On the one hand, apoptosis was determined by flow cytometry as the percentage of 
cells in the sub-G1 region (hypodiploidy) in cell cycle analysis as previously described 
(Gajate et al., 2000).  
On the other hand, an Annexin V-FLUOS Apoptosis Detection Kit (Roche Molecular 
Biochemicals, Barcelona, Spain) was used according to the manufacturer's protocol. 
The percentage of cells that underwent apoptosis was quantified by flow cytometry on a 
FACSCalibur flow cytometer using CellQuest software and analyzed with FlowJo 
software. All experiments were performed in triplicate.  
 
2.8. Statistical Analysis 
Data are presented as a mean of three or more independent experiments, with error 
bars indicating the standard deviation. The inhibitory concentration 50 (IC50) values 
were calculated with GraphPad Prism software using the sigmoidal dose-response 
function (variable slope). Statistical comparisons were performed by analysis of 
variance, and further post-hoc testing was conducted using the statistical software 
GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). Non-parametric 
statistics (Kruskal-Wallis test followed by Dunn's Post Hoc test) were used for the 
analysis of Sub-G1 data. Cell viability, cell cycle and apoptosis statistical analyses were 
performed with two-way Anova and Bonferroni post hoc tests. Groups that are 
significantly different are indicated in the figures as *p < 0.05, **p < 0.01 and ***p < 
0.001. 
 
3. Results and discussion 
ET is an anti-tumor drug belonging to the ALPs family that has been employed for the 
treatment of various malignancies with promising results (Estella-Hermoso de Mendoza 
et al., 2009a; Mollinedo et al., 2010a; Na and Surh, 2008; Shafer and Williams, 2003). 
However, due to its nature, ET presents several drawbacks that have to be overcome 
by protecting the molecule. Nanotechnology applications in medicine have successfully 
enhanced the therapeutic efficacy of many anti-cancer drugs. In fact, the 
nanoencapsulation approach of ET has yielded promising results (Estella-Hermoso de 
Mendoza et al., 2012; Lasa-Saracibar et al., 2013), demonstrating that the 
vehiculization strategy is essential to ensure the effectiveness of ET (Estella-Hermoso 
de Mendoza et al., 2012). Such hopeful results prompted us to develop ET-loaded LN 
for studying its in vitro anti-tumor effect compared to the free drug in breast cancer. 
 
3.1. Nanoparticle characterization 
ET-loaded LNs were produced by a solvent-free hot homogenization method followed 
by high shear homogenization and ultrasonication, and were freeze-dried afterwards. 
LN were characterized in terms of size, zeta potential, encapsulation efficiency and drug 
loading. As shown in Table 1, we were able to obtain submicron-sized LN with 
homogeneous diameter. All data are expressed as mean value ± standard deviation. 
Both drug-free LN and ET-LN mean diameters were below 150 nm, indicating that LN 
developed are suitable for both gastrointestinal and intravenous administration without 
entailing embolism risks (Charman and Stella, 1992; Estella-Hermoso de Mendoza et 
al., 2009c; Varshosaz et al., 2010; Zimmermann et al., 2000). Furthermore, the 
incorporation of edelfosine into LN proved to significantly decrease the hemolytic toxicity 
of the free drug in a previous work published by our group (Estella-Hermoso de 
Mendoza et al., 2012). PDI was below 0.3, proving that the developed particles were 
monodisperse (Anton et al., 2008; Estella-Hermoso de Mendoza et al., 2008). Zeta 
potential of LN, a parameter that indicates the stability of colloid dispersions, was not 
affected by the incorporation of edelfosine (-28.46 for B-LN and -27.07 mV for ET-LN). 
In general, zeta potential values of -30 mV are enough for suitable stabilization (Estella-
Hermoso de Mendoza et al., 2009c). Therefore, in our case the zeta-potential values 
obtained indicate that the formulations presented a good physical stability and that the 
LN generated would not induce cell membrane instability (Estella-Hermoso de Mendoza 
et al., 2009c; Müller RH, 1996). The LN obtained showed good encapsulation efficiency 
of 58.80%, presenting a drug loading of 30 μg ET per mg of formulation.  
 
3.2.  ET anti-tumor effect is enhanced when drug is encapsulated in LN 
As the encapsulation procedure may modify the anti-tumor potential of ET, we analyzed 
the effectiveness of the ET-LN in MCF7 breast cancer cells. In order to evaluate the 
cytotoxic potential of the encapsulated drug, MCF7 cells were cultured for 72 h in the 
presence of growing concentrations of ET or equivalent concentrations of ET-LN. B-LN 
were also tested as control. Cytotoxicity was assessed by the comparison of IC50 
values. The optimized ET-LN were effective in inhibiting the proliferation of MCF7 breast 
cancer cell line at an IC50 concentration of 12.9 (± 2.23) μg/mL, whereas the 
corresponding IC50 values of the free drug and B-LN were 17.8 (± 4.06) and 28.7 (± 
8.08) μg/mL respectively (Fig. 1).  
The efficacy of the drug may also be assessed by visualizing changes in the 
appearance and size of cells after being incubated with the different treatments. Optical 
inspection of the MCF7 cell cultures by light microscopy revealed morphological 
changes in MCF7 after the treatment with either ET or ET-LN. Compared with untreated 
controls and with cells incubated with B-LN, treated cell cultures showed expression of 
intracellular vesicles (indicated with arrows in Fig. 2A) and presented distorted and 
detached rounded cells that had shrunk. These signs are indicative of cell death 
(Kroemer et al., 2009). In fact, the percentage of viable cells was dramatically 
diminished in ET-LN-treated cultures in comparison to cells treated with B-LN. 
Moreover, the observed decrease was significantly higher than that of the cells treated 
with the free drug, confirming that the encapsulation strategy increased the cytotoxic 
potential of ET (Fig. 2B). This effect was time-dependent and reached statistical 
significance after 72 h of incubation. 
Hence the developed ET-LN formulation maintained the anti-tumor activity of ET; 
moreover, ET-LN were 1.37 times more effective in inducing cell death in MCF7 cells 
than the free drug, and produced a remarkable decrease in cell viability.  
Our results are in accordance with previously reported work, in which the cytotoxic 
effect of ET against other tumor types was found to be significantly improved when 
encapsulated in LN (Estella-Hermoso de Mendoza et al., 2009b; Estella-Hermoso de 
Mendoza et al., 2011; Lasa-Saracibar et al., 2013), thereby giving additional support to 
the usefulness of encapsulating the ET in LN. 
 
3.3. Cell cycle arrest and induction of apoptotic mechanisms by ET and ET-LN in MCF7 
breast cancer cells 
The aforementioned decrease in cell viability may be caused by an abnormality in the 
cell cycle or in the cell growth. Therefore, MCF7 cells were stained with PI and 
subsequently cell cycle status was examined by flow cytometry (Fig. 3A). In cells grown 
either with ET or ET-LN, a cell accumulation in G1 stage, with a concomitant reduction 
of cells in S phase, was detected (Fig. 3B). It has been reported that ET-treated cells 
may accumulate in the G0/G1 and G2/M phases of the cell cycle, due to an inhibition of 
cytokinesis (Mollinedo et al., 2004; Pushkareva et al., 1999), although the cell cycle 
blockage induced by ET has more commonly been detected at the G2/M stage (Lasa-
Saracibar et al., 2013; Mollinedo et al., 2004; Nieto-Miguel et al., 2007). This suggests 
that ET may provoke cell cycle arrest by influencing diverse molecular pathways, and 
the phase where the cell cycle is blocked would depend on the cell signaling routes 
characteristic of each cancer cell type. 
On the other hand, the aforementioned cell cycle arrest may reflect defective cell growth 
or an induction of cell death mechanisms caused by the effects that ET exerts in tumor 
cells. Moreover, the disturbance of phospholipid metabolism and the interference in the 
membrane interactions with signaling molecules caused by ET may induce cellular 
stress, deregulation of apoptotic pathways, growth inhibition and cell cycle arrest and 
apoptosis (Mollinedo et al., 2010b; Van Blitterswijk and Verheij, 2008; Van der Luit et 
al., 2007). In addition, ET has been described to induce apoptosis through the 
aggregation of Fas/CD95 in clustered rafts (Gajate et al., 2009; Gajate and Mollinedo, 
2007). Accordingly, we analyzed the apoptotic status of treated-MCF7 cultures. Firstly, 
the percentage of cells in the sub-G1 region (hypodiploidy) in cell cycle analysis was 
determined by staining the cells with PI. As shown in Fig. 4A, the sub-G1 subset of 
MCF7 cells exhibited a strong increase in cells treated with either ET or ET-LN after 72 
h of treatment. Along the lines of previous reported analyses of sub-G1 of ET-LN in 
several cancer malignancies (Mollinedo et al., 2010b), our data indicates that MCF7 
undergoes apoptosis in the presence of ET in the culture media. However, the 
extensive DNA fragmentation and loss of DNA fragments is not exclusive to apoptotic 
death. Besides, the sub-G1 peak may represent apoptotic cells, as well as nuclear 
fragments, clusters of chromosomes, micronuclei or nuclei with normal DNA content but 
altered chromatin structure and diminished accessibility of fluorochrome to DNA 
(Darzynkiewicz et al., 2001; Riccardi and Nicoletti, 2006).  
The aforementioned effect may dim the DNA degradation caused by apoptosis. 
Consequently, to further characterize this cell death mechanism, cells were treated in 
identical conditions, stained with annexin V-FITC and PI dyes and subsequently 
analyzed by flow cytometry to determine the percentage of viable, early apoptotic, and 
late apoptotic/necrotic sub-populations in MCF7-treated cultures (Fig. 4B and C). As is 
shown in Fig. 4C, the early apoptosis and the late apoptosis/necrosis/death cell subsets 
were increased in treated cells in comparison to their corresponding control. This 
induction was detected even with lower concentrations of the treatments (data not 
shown), and was statistically significant after 48 and 72 h of incubation with 20 μg/mL of 
ET or equivalent concentrations of ET-LN. Interestingly, the induction of cell death was 
stronger in ET-LN than in cells grown in the presence of the free drug, compared to their 
equivalent B-LN controls. In particular, the cell late apoptosis/necrosis/death subset was 
highly increased in cells grown in the presence of 20 μg/mL of ET-LN for 72 h. The 
results are in agreement with those recently reported by Lasa-Saracíbar et al in 
leukemic cells when treated with the free drug and ET-LN (Lasa-Saracibar et al., 2013). 
Accordingly, our results show that both ET and ET-LN displayed a pro-apoptotic activity 
against MCF7 breast cancer cells in a time- and dose-dependent manner. This effect 
was probably caused by the characteristic controlled drug release of LN. In addition, 
there was a substantial increment in the population of cells that underwent apoptosis in 
the presence of ET-LN in comparison to the free drug treatment.  
The results presented indicate that the cytotoxic effect of ET on MCF7 was considerably 
enhanced when the drug was entrapped in LN. Moreover, although ET was able to 
promote both an apoptotic and a cytostatic effect in MCF7, such anti-tumor effects were 
considerably enhanced in ET-LN-treated cells.  
 
4. Conclusions 
The data presented in this paper provide evidence that entrapping ET in LN entails an 
improvement in its efficacy when treating MCF7 breast cancer cells, leading to a 
moderate cell cycle arrest. Besides, ET-LN induced apoptosis in a time-and dose-
dependent manner to a greater extent in comparison with the treatment using the free 
drug, suggesting that encapsulating ET in LN is essential to improve the efficacy of the 
drug. Molecular cell death mechanisms must be studied in greater depth in order to 
further characterize the induction process by which ET-LN exert their anti-tumor effect. 
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FIGURE CAPTIONS 
Fig. 1. MTT assay was used to determine the dose-response curve in MCF7 cells at 72 
h of incubation with different doses of free edelfosine (ET), unloaded (B-LN) or drug-
loaded (ET-LN). IC50 values were calculated using the sigmoidal dose-response 
function. DMSO-treated cells were included as positive control of cell death.  
 
Fig. 2. Cytotoxic effects in MCF-7 cells after treatment with 20  μg/mL of edelfosine (ET) 
or equivalent concentrations ET-loaded nanoparticles (ET-LN). B-LN were also tested 
as control. A) Light microscope images revealed that at 48 h treated groups showed 
unattached and distorted cells and the expression of intracellular vesicles (indicated 
with arrows). B) Trypan blue assay was used to determine cell viability of treated cells at 
48 and 72 h. Untreated (WT) cells were included as control. *** p<0.001 vs. 
corresponding ET group by two-way ANOVA (Bonferroni post-test).  
 
Fig. 3. Free and nanoencapsulated drug effect in cell cycle after 48 and 72 h of 
incubation. Cells were treated with medium, blank-LN, free ET and drug-loaded LN at a 
dose equivalent to 20 μg/mL of edelfosine (ET). (A) Cell cytometry images of treated 
cells. (B) Quantification of cell cycle peaks. 
*p<0.05; **p<0.01; vs. control by two-way ANOVA (Bonferroni post-test).  
 
Fig. 4. Apoptosis analysis of MCF7 after incubation with medium (WT), blank-LN (B-
LN), free edelfosine (ET) and drug-loaded LN (ET-LN) at a dose equivalent of 20 μg/mL 
of edelfosine. Apoptosis was firstly assessed with quantification of DNA content in cells 
and determination of sub-G1 cell subset (A) and subsequently analyzed with flow 
cytometry (B). 
*p<0.05; vs control with Kruskall-Wallis test (Dunns post-hoc test) for sub-G1 analysis, 
*p<0.05 **p<0.01; ***p<0.001 vs. B-LN control by two-way ANOVA (Bonferroni post-
test).  
 
 
